Phillip Gulley, NP
Primary Care · San Antonio, TXNPI 1346832854
Payments from drug & device makers
Across 1,176 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Neurocrine Biosciences, Inc.$2K
- AbbVie$2K
- UCB, Inc.$2K
- Neurelis, Inc.$2K
- Bristol Myers Squibb$1K
- plus $13K from 54 others
What the payments were for
- Travel & lodging$1,6947%
- Food & beverage$21,22292%
- Education$1201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Percept$1,457
- GOCOVRI$268
- VNS Therapy$246
- TYSABRI$214
- PERCEPT PC BRAINSENSE$136
- AIMOVIG$122
How this compares
$23,036 in reported general payments places this provider in the 95th percentile of 563 primary care providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 37 | $742,884 |
| IngrezzaValbenazine Tosylate | 23 | $193,660 |
| Austedo XrDeutetrabenazine | 15 | $186,143 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 17 | $122,348 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 14 | $97,902 |
| NuplazidPimavanserin Tartrate | 12 | $97,209 |
| Aimovig AutoinjectorErenumab-Aooe | 73 | $85,161 |
| Oxtellar XrOxcarbazepine | 15 | $57,854 |
| Nurtec OdtRimegepant Sulfate | 38 | $53,496 |
| RytaryCarbidopa/Levodopa | 48 | $50,543 |
| AptiomEslicarbazepine Acetate | 18 | $36,644 |
| XcopriCenobamate | 29 | $34,172 |
| RexultiBrexpiprazole | 20 | $31,569 |
| NuedextaDextromethorphan Hbr/Quinidine | 15 | $22,883 |
| KeppraLevetiracetam | 13 | $19,625 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $90 | $742,88437 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,879 | $193,66023 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $622 | $186,14315 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $45 | $97,90214 claims |
| Acadia Pharmaceuticals IncNuplazid | $911 | $97,20912 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $158 | $57,85415 claims |
| PfizerNurtec Odt | $260 | $53,49638 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $152 | $52,37668 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $176 | $36,64418 claims |
| SK Life Science, Inc.Xcopri | $386 | $34,17229 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $201 | $31,56920 claims |
| AbbVieQulipta, Ubrelvy | $1,835 | $28,05526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 563 primary care providers in Texas.
Other primary care in San Antonio
- Charlotte BallardSan Antonio$9K
- Christopher LoganSan Antonio$8K
- Lydia Chapa WilsonSan Antonio$7K
- Jing LiSan Antonio$6K
- Lauryn SaenzSan Antonio$5K
- Brittany CurrySan Antonio$4K
- Martha RuizSan Antonio$3K
- Ryan WenclSan Antonio$3K
- Gabriella MutschlechnerSan Antonio$3K
- Mary GibbensHouston$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.